Antithrombotic Treatment Strategies in Cervical Artery Dissection (TREAT-CAD 2)
Antiplatelet Versus Anticoagulation TREATment Strategies in Cervical Artery Dissection - TREAT-CAD 2 - A Multicenter, Randomized, Two-arm Parallel Group, Open-label, Blinded Endpoint, Pragmatic Trial
The goal of this clinical randomised controlled trial is to compare two treatment strategies - antiplatelet treatment strategy versus anticoagulation treatment strategy - in patients with acute, ischemic Cervical Artery Dissection (CAD). The study population includes patients presenting with any (clinical or imaging) signs of cerebral ischemia due to CAD.
The trial aims to estimate the net effect of antiplatelet versus anticoagulation treatment strategies on the composite primary outcome including recurrent ischemic stroke, major bleeding, or vascular death at 90 days (±2 weeks) after randomization.
Participants will:
- be randomly allocated to antiplatelet treatment strategy or anticoagulation treatment strategy
- receive treatment according to assigned strategy for the study period of 90 days
- be followed up for 90 days (±2 weeks) after randomization
- undergo clinical assessments to monitor for stroke recurrence, bleeding events, and vascular death Participant reported outcomes will be assessed both at 90 days (±2 weeks) and 12 months (± 4 weeks) after enrolment and will also expand to measures of quality of life and mental health outcomes.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Written informed consent (according to requirements by national legislation)
Onset/visualization of acute cerebral ischemia (≤ 3 days prior to randomization) attributable to CAD (either)
- CLINICAL ISCHEMIA: onset of acute ischemic stroke (including retinal infarct) or transient ischemic attack (including amaurosis fugax) attributable to CAD OR
- ISCHEMIA WITHOUT CORRESPONDING SYMPTOMS: visualization of acute ischemic lesion on diffusion weighted imaging attributable to CAD
Clinical MRI with suitable sequences for CAD diagnosis
- available OR
- scheduled to be performed before discharge (if not performed before enrolment)
Diagnosis of Cervical Artery Dissection (i.e. extracranial carotid and/or vertebral artery) by MRI/A or CTA based on the presence of the following criteria (at least one)
- Mural hematoma OR
- Long tapering stenosis OR
- Intimal flap OR
- Double lumen OR
- Flame-like occlusion of the dissected artery
Exclusion Criteria:
- Contraindications to either antiplatelets or oral anticoagulation therapy
- Other indication than CAD for full dose oral anticoagulation
- Contraindications for performance of MRI
- Age < 18 years
- Female patients who are either pregnant or breastfeeding (pregnancy testing prior to start of treatment will follow the standard operating procedures of clinical routine at participating sites)
Thrombolysis and/or endovascular treatment (EVT) is/are not considered an exclusion criterion.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Antiplatelet Treatment Strategy
|
Includes aspirin (ASA) or clopidogrel monotherapy or dual antiplatelet therapy (ASA + clopidogrel), at the choice of the treating physician but adhering to latest ESO guideline
|
|
実験的:Anticoagulation Treatment Strategy
|
Includes vitamin K antagonists (phenprocoumon, acenocoumarol, warfarin) with target INR 2.0-3.0 and heparin/LMWH bridging if needed or DOACs (apixaban, edoxaban, dabigatran, rivaroxaban) - at the choice of the treating physician but adhering to latest ESO guideline
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Net effect of antiplatelet treatment strategy versus anticoagulation treatment strategy
時間枠:From enrollment to day 90 (± 2 weeks)
|
The primary endpoint is a composite of the occurrence of (1) recurrent ischemic stroke, (2) major bleeding (extracranial or intracranial), or (3) vascular death
|
From enrollment to day 90 (± 2 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Occurrence of each single component of the primary composite outcome measure
時間枠:From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
|
|
- Functional neurological outcome (mRS)
時間枠:From enrollment to day 90 (± 2 weeks)
|
absolute difference and shift in favorable outcome (defined as mRS ≤ 2)
|
From enrollment to day 90 (± 2 weeks)
|
|
All-cause mortality
時間枠:From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
|
|
Recurrence of Cervical Artery Dissection
時間枠:From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
|
|
Patient-reported outcome measure on global health (PROMIS-10)
時間枠:From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
|
|
Health related quality of life (EQ-5D Visual Analog scale)
時間枠:From enrollment to day 90 (± 2 weeks)
|
From enrollment to day 90 (± 2 weeks)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2026-01009
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。